Enjoy complimentary customisation on priority with our Enterprise License!
The anti-malarial medicines market share is expected to increase by USD 287.52 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 5%. This anti-malarial medicines market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The anti-malarial medicines market report also offers information on several market vendors, including AstraZeneca Plc, Bayer AG, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Mylan NV, Novartis AG, Pfizer Inc., Sanofi SA, and Sun Pharmaceutical Industries Ltd. among others. Furthermore, this report extensively covers anti-malarial medicines market segmentation by product (artemisinin compounds, quinolines and related compounds, and other compounds) and geography (Asia, ROW, Europe, and North America).
Download the Free Report Sample to Unlock the Anti-malarial Medicines Market Size for the Forecast Period and Other Important Statistics
The strong funding to eradicate malaria is notably driving the anti-malarial medicines market growth, although factors such as drug-resistant pathogens may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the anti-malarial medicines industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Anti-malarial Medicines Market Driver
One of the key factors driving growth in the anti-malarial medicines market is the growing incidence of malaria. The growing incidence of malaria has increased the need for malaria rapid diagnostic devices, which can provide rapid test results and help in the diagnosis of the disease. The number of malaria cases is higher in Africa and Southeast Asian countries, owing to the lack of adequate healthcare infrastructure and less knowledge about parasitic infectious diseases. In 2018, the CDC reported that malaria was endemic in 91 countries and subtropics. According to WHO, there were almost 229 million cases globally of malaria in 2019. According to the OECD, about 2.3 million people across the world are at risk from malaria. Around 1 billion people in APAC, such as that in Papua New Guinea, Solomon Islands, Pakistan, India, Nepal, the Philippines, Indonesia, Myanmar, the Lao PDR, Cambodia, Thailand, China, Vietnam, Bangladesh, the Republic of Korea, and Malaysia, are at high risk of malaria. According to a report published by the CDC in 2019, around 219 million estimated cases of malaria were reported across the world. In addition, in the US, approximately 1,700 cases are diagnosed every year. To support and provide early diagnosis and treatment, CDC provides information related to malaria through its CDC Division of Parasitic Diseases and Malaria diagnostic website, which is available 24 hours a day.
Key Anti-malarial Medicines Market Trend
The development of prophylactic treatment is an antimalarial medicines market trend that is expected to have a positive impact in the coming years. The global anti-malarial medicines market is currently dominated by artemisinin compounds and by quinoline and its derivatives. These compounds are helpful only if the disease is effectively diagnosed, which itself is a challenge because of the complex life cycle of the disease. To overcome this, the market is inching toward developing a preventive mechanism against malaria in the form of various vaccines. All these years, the focus was on developing therapeutics for the treatment of malaria. However, the malaria parasites have a complex life span, and the current therapeutics do not offer lifelong protection. To overcome this challenge, many vaccines are being developed, some of which are expected to be marketed during the forecast period. For instance, RTS,S/AS01 by GlaxoSmithKline is an advanced malaria vaccine candidate. The development of such advanced treatment methods will fuel the growth of the global anti-malarial medicines market during the forecast period.
Key Anti-malarial Medicines Market Challenges
Drug-resistant pathogens are a major hindrance to the anti-malarial medicines market growth. Human malaria is caused mainly by four Plasmodium species, such as P. vivax, P. falciparum, P. ovale, and P. malariae. Some of these species are resistant to a single drug, while some are resistant to multiple drugs. This increases the probability and severity of the disease. Multidrug-resistant microbes are a major threat to human health currently. Such microbes change themselves to protect against the antimicrobial agent used, thereby developing resistance to the drug. This happens primarily due to the irrational use of drugs. The incorrect prescription of drugs by physicians or the incorrect dosing or course taken by patients, along with the increased use of similar drug ingredients in the agriculture and animal husbandry industries, leads to the development of such resistance. The commonly used anti-infective drugs thus become ineffective against the microbes, leading to the aggravation of the disease. This is reducing the acceptance of many anti-malarial medicines. In many countries, P. falciparum has become a chloroquine-resistant microbe, which leads to a worldwide increase in malaria-related mortality and morbidity rates. Thus, the drug resistance of microbes is expected to hinder the growth of the global anti-malarial medicines market during the forecast period.
This anti-malarial medicines market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the anti-malarial medicines market encompasses successful business strategies deployed by the key vendors. The anti-malarial medicines market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The anti-malarial medicines market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Product
6 Customer landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.